Responding to High Drug Prices: What Should Patients and Payors Do?

May 11, 2018: Health Policy and Bioethics Consortium
12:30 - 2 p.m.

The high cost of prescription drugs reduces patient accessibility to medications, which can lead to worse health outcomes. The process of translating a drug's price -- from the amount that the manufacturer sets, to the cost paid by patients and health care institutions -- is complex and involves a number of different actors. Is it possible to develop policies that optimize pharmaceutical spending to ensure that patients can access the products they need and to promote cost-effective use of products?


Michael S. Sherman, MD, MBA, MS
Chief Medical Officer
and Senior Vice President 
Harvard Pilgrim Health Care
Lecturer, Harvard Medical School 

Timothy G. Ferris, MD, MPH 
Chief Executive Officer
Mass General Physicians Organization 
Massachusetts General Hospital   
Associate Professor of Medicine
Harvard Medical School 

Ameet Sarpatwari, JD, PhD 
Assistant Director
Program On Regulation, Therapeutics, And Law (PORTAL)
Instructor in Medicine, Harvard Medical School


This event is free and open to the public, but registration is required. 

The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations. They are organized by the Center for Bioethics at Harvard Medical School and the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.

Health Policy and Bioethics